Sign In
Free Newsletter
Novartis plans 114 more job cuts at East Hanover HQ
The latest layoffs come as the company continues to restructure while investing in new domestic facilities and pipelines.
Novartis to buy Excellergy for $2B to boost allergy drugs
Novartis will acquire the California biotech, adding next-gen IgE therapy Exl-111 to its portfolio in the first half of 2026.
J&J to acquire Connecticut biotech in $3.05B oncology deal
Johnson & Johnson's latest target, Halda Therapeutics, will add prostate cancer therapy HLD-0915 along with other early-stage assets.
Novartis’ $12B Avidity acquisition to expand neuroscience pipeline
The play for San Diego-based Avidity Biosciences will add RNA therapeutics that target rare genetic neuromuscular diseases.
Genmab to acquire Merus in $8B biotech deal
The move will add a treatment for head and neck cancer to the Plainsboro-based buyer's pipeline.
Novartis to acquire Regulus in $1.7B kidney drug deal
The move adds a potential ADPKD (autosomal dominant polycystic kidney disease) treatment as well as a microRNA platform to its therapy pipeline.
